Literature DB >> 9543273

Empirical therapy for nonhospitalized patients with community-acquired pneumonia. Study Group of General Practitioners.

H Laurichesse1, F Robin, L Gerbaud, P Pochet, F Gourdon, J Beytout, M Rey.   

Abstract

A prospective survey involving a group of 95 general practitioners (GPs) in France was conducted to describe antibiotic therapy prescribed for out-patients with community-acquired pneumonia (CAP). A total of 173 cases of CAP, defined by the association of fever and pulmonary focal crackles and/or radiological changes consistent with a pulmonary infection, were reported between February 1993 and March 1994: 84 males and 89 females (mean age: 48 yrs) of whom 45% had no underlying disease. Nineteen (11%) were immediately hospitalized and the remaining 154 out-patients were treated without microbiological investigation. First-line antibiotic therapy was amoxicillin or amoxicillin-clavulanic acid combination (57%), a first or second generation cephalosporin (12%), ceftriaxone (8%), oral broad-spectrum cephalosporin (3%), a macrolide (16%), a tetracycline (1%) and a fluoroquinolone (2%). A total of 120 (78%) patients recovered with no change in treatment and 34 (22%) patients failed to improve: 18 were hospitalized and 16 had a second-line therapy, mainly a macrolide or a quinolone. Five patients died at hospital. The overall mortality was 3%, and 14% in hospitalized patients. Empirical therapy using a betalactam to target a presumed pneumococcal infection, in agreement with European guidelines, is appropriate for out-patients with mild lobar community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543273     DOI: 10.1183/09031936.98.11010073

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

1.  Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Authors:  Michael Iskedjian; John H Walker; Gaston De Serres; Thomas R Einarson
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Defining disease heterogeneity to guide the empirical treatment of febrile illness in resource poor settings.

Authors:  Lisa J White; Paul N Newton; Richard J Maude; Wirichada Pan-ngum; Jessica R Fried; Mayfong Mayxay; Rapeephan R Maude; Nicholas P J Day
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

3.  Suspected community-acquired pneumonia in an ambulatory setting (CAPA): a French prospective observational cohort study in general practice.

Authors:  Henri Partouche; Céline Buffel du Vaure; Virginie Personne; Chloé Le Cossec; Camille Garcin; Alain Lorenzo; Christian Ghasarossian; Paul Landais; Laurent Toubiana; Serge Gilberg
Journal:  NPJ Prim Care Respir Med       Date:  2015-03-12       Impact factor: 2.871

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.